CAMBRIDGE, Mass., Nov. 15 /PRNewswire-FirstCall/ -- Xanthus Life Sciences, Inc., a privately-held oncology drug development company, today announced that J. Kris Piper has joined the Xanthus management team as Vice President of Regulatory Affairs and Quality Assurance.
“Kris brings to Xanthus an extensive set of global regulatory accomplishments in both therapeutic and imaging product development which, I know from our prior working experience, will complement and strengthen the considerable expertise of our senior management team. In prior positions, Kris has been responsible for the filing and subsequent approval of over 20 NDAs, three of which were priority review products. Additionally, Kris has also been responsible for implementing the various policies and procedures necessary to assure product quality and regulatory compliance,” stated Richard T. Dean, Ph.D., President and CEO of Xanthus. “We are pleased to welcome Kris to Xanthus and look forward to the important contributions he will make as we advance our pipeline of oncology therapeutics and expand into new indications of unmet medical need.”
J. Kris Piper joins Xanthus from Bracco S.p.A. where he was Vice President Global Preclinical and Clinical Regulatory Affairs. Prior to Bracco, Mr. Piper was Vice President Regulatory Affairs at Schering AG where he was responsible for all regulatory affairs activities for products at Schering’s Berlex and Diatide subsidiaries. Mr. Piper also held Director and Manager level positions in Regulatory Affairs and Quality Assurance for Mallinckrodt Medical, Inc., American Hospital Supply Corporation, Searle Pharmaceuticals, Inc. and Bayer Healthcare’s Cutter Laboratories, Inc. Mr. Piper is a graduate of University of California, Davis where he also received his Master of Science Degree in Physiology.
About Xanthus Life Sciences, Inc.
Xanthus Life Sciences, Inc. is developing a portfolio of novel, clinical- stage, small-molecule oncology candidates through a management team whose accomplished track record encompasses all aspects of drug development, from discovery through regulatory approval and commercialization. The Company is applying its expertise both to advance its current pipeline and expand it into indications of unmet medical need beyond oncology.
Xanthus is headquartered in Cambridge, Massachusetts with an additional facility in Montreal, Quebec. More information is available at http://www.xanthus.com.
Contacts: Kari Watson, MacDougall Biomedical Communications, Inc. kwatson@macbiocom.com or (508) 647-0209 John A. McCarthy, Jr., Senior Vice President and Chief Financial Officer, Xanthus Life Sciences, Inc. - (617) 225-0522 x125
Xanthus Life Sciences, Inc.
CONTACT: Kari Watson of MacDougall Biomedical Communications, Inc.,kwatson@macbiocom.com, +1-508-647-0209; or John A. McCarthy, Jr., SeniorVice President and Chief Financial Officer of Xanthus Life Sciences, Inc.,+1-617- 225-0522 ext 125
Web site: http://www.xanthus.com/
